Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 69

1.

Antidepressant fluvoxamine reduces cerebral infarct volume and ameliorates sensorimotor dysfunction in experimental stroke.

Sato S, Kawamata T, Kobayashi T, Okada Y.

Neuroreport. 2014 Jul 9;25(10):731-6. doi: 10.1097/WNR.0000000000000162.

PMID:
24709917
3.

In vivo neuroprotective effects of ACEA 1021 confirmed by magnetic resonance imaging in ischemic stroke.

Petty MA, Neumann-Haefelin C, Kalisch J, Sarhan S, Wettstein JG, Juretschke HP.

Eur J Pharmacol. 2003 Aug 1;474(1):53-62.

PMID:
12909195
4.

Neuroprotective effects of a postischemic treatment with a bradykinin B2 receptor antagonist in a rat model of temporary focal cerebral ischemia.

Lumenta DB, Plesnila N, Kläsner B, Baethmann A, Pruneau D, Schmid-Elsaesser R, Zausinger S.

Brain Res. 2006 Jan 19;1069(1):227-34. Epub 2005 Dec 27.

PMID:
16378603
6.

AMPA receptor antagonist, YM90K, reduces infarct volume in thrombotic distal middle cerebral artery occlusion in spontaneously hypertensive rats.

Yao H, Ibayashi S, Nakane H, Cai H, Uchimura H, Fujishima M.

Brain Res. 1997 Apr 4;753(1):80-5.

PMID:
9125434
7.

Wide therapeutic time window for nimesulide neuroprotection in a model of transient focal cerebral ischemia in the rat.

Candelario-Jalil E, González-Falcón A, García-Cabrera M, León OS, Fiebich BL.

Brain Res. 2004 May 8;1007(1-2):98-108.

PMID:
15064140
8.

Strategies to improve post-stroke behavioral recovery in aged subjects.

Buga AM, Bălşeanu A, Popa-Wagner A, Mogoantă L.

Rom J Morphol Embryol. 2009;50(4):559-82.

9.

Treatment with afobazole at delayed time points following ischemic stroke improves long-term functional and histological outcomes.

Katnik C, Garcia A, Behensky AA, Yasny IE, Shuster AM, Seredenin SB, Petrov AV, Seifu S, McAleer J, Willing A, Cuevas J.

Neurobiol Dis. 2014 Feb;62:354-64. doi: 10.1016/j.nbd.2013.10.011. Epub 2013 Oct 16.

PMID:
24141021
10.

Suramin reduces infarct volume in a model of focal brain ischemia in rats.

Kharlamov A, Jones SC, Kim DK.

Exp Brain Res. 2002 Dec;147(3):353-9. Epub 2002 Oct 17.

PMID:
12428143
11.
12.

NXY-059, a novel free radical trapping compound, reduces cortical infarction after permanent focal cerebral ischemia in the rat.

Zhao Z, Cheng M, Maples KR, Ma JY, Buchan AM.

Brain Res. 2001 Aug 3;909(1-2):46-50.

PMID:
11478919
13.

Neuroprotection by LY341122, a novel inhibitor of lipid peroxidation, against focal ischemic brain damage in rats.

Huh PW, Belayev L, Zhao W, Clemens JA, Panetta JA, Busto R, Ginsberg MD.

Eur J Pharmacol. 2000 Feb 11;389(1):79-88.

PMID:
10686299
14.

Cognition and depression: the effects of fluvoxamine, a sigma-1 receptor agonist, reconsidered.

Hindmarch I, Hashimoto K.

Hum Psychopharmacol. 2010 Apr;25(3):193-200. doi: 10.1002/hup.1106. Review.

PMID:
20373470
15.

SB 234551 selective ET(A) receptor antagonism: perfusion/diffusion MRI used to define treatable stroke model, time to treatment and mechanism of protection.

Legos JJ, Lenhard SC, Haimbach RE, Schaeffer TR, Bentley RG, McVey MJ, Chandra S, Irving EA, Andrew A Parsons, Barone FC.

Exp Neurol. 2008 Jul;212(1):53-62. doi: 10.1016/j.expneurol.2008.03.011. Epub 2008 Mar 25.

PMID:
18462720
16.

Sigma-1 receptor agonist fluvoxamine for delirium in older adults.

Hashimoto K, Furuse T.

Int J Geriatr Psychiatry. 2012 Sep;27(9):981-3. doi: 10.1002/gps.2809. Epub 2011 Nov 3. No abstract available.

PMID:
22052610
17.

Neurobehavioral consequences of induced spreading depression following photothrombotic middle cerebral artery occlusion.

Alexis NE, Back T, Zhao W, Dietrich WD, Watson BD, Ginsberg MD.

Brain Res. 1996 Jan 15;706(2):273-82.

PMID:
8822367
18.

Can the sigma-1 receptor agonist fluvoxamine prevent schizophrenia?

Hashimoto K.

CNS Neurol Disord Drug Targets. 2009 Dec;8(6):470-4. Review.

PMID:
19702566
19.

Neuroprotective effect of treatment with human albumin in permanent focal cerebral ischemia: histopathology and cortical perfusion studies.

Liu Y, Belayev L, Zhao W, Busto R, Belayev A, Ginsberg MD.

Eur J Pharmacol. 2001 Oct 5;428(2):193-201.

PMID:
11675036

Supplemental Content

Support Center